[{"indications": "Indications\u00a0see preparations below", "name": "LAMIVUDINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.1 HIV infection", "Nucleoside reverse transcriptase inhibitors", "LAMIVUDINE"], "cautions": "Cautions\u00a0\n(From Nucleoside reverse transcriptase inhibitors: British National Formulary)\nNucleoside reverse transcriptase inhibitors; interactions: Appendix 1 (lamivudine)Chronic hepatitis B\u00a0Recurrent hepatitis\r\nin patients with chronic hepatitis B may occur on discontinuation of lamivudine. When treating chronic hepatitis\r\nB with lamivudine, monitor liver function tests\r\nevery 3 months, and viral markers of hepatitis B every 3\u20136 months,\r\nmore frequently in patients with advanced liver disease or following\r\ntransplantation (monitoring to continue for at least 1 year after\r\ndiscontinuation)", "side-effects": "Side-effects\u00a0see notes above; also peripheral neuropathy, muscle\r\ndisorders including rhabdomyolysis, nasal symptoms, alopecia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/82000.htm", "doses": ["See preparations below", "chronic hepatitis B infection either with\r\ncompensated liver disease (with evidence of viral replication and\r\nhistology of active liver inflammation or fibrosis) when first-line\r\ntreatments cannot be used, or (in combination with\r\nanother antiviral drug without cross-resistance to lamivudine) with\r\ndecompensated liver disease, 100\u00a0mg daily; child [unlicensed indication] 2\u201311 years, 3\u00a0mg/kg once daily (max. 100\u00a0mg\r\ndaily); 12\u201317 years, adult dose", "Patients receiving lamivudine for concomitant HIV infection should continue to receive lamivudine in a dose appropriate for HIV infection"], "pregnancy": "Pregnancy\u00a0see Pregnancy"}]